A Phase II Study of Etirinotecan Pegol (NKTR 102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Brain metastases; Breast cancer; Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
- 23 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 23 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 20 Dec 2016 New trial record